This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

At oral proceedings before an opposition division of the EPO NattoPharma's European patent no. 1153548 was revoked for lack of inventive step. NattoPharma holds the opinion that the decision is incorrect and will immediately be filing an appeal against the decision.